Figure 1:

```
        10          20          30          40          50          60
MQSKVLLAVA LWLCVETRAA SVGLPSVSLD LPRLSIQKDI LTIKANTTLQ ITCRGQRDLD

        70          80          90         100         110         120
WLWPNNQSGS EQRVEVTECS DGLFCKTLTI PKVIGNDTGA YKCFYRETDL ASVIYVYVQD

       130         140         150         160         170         180
YRSPFIASVS DQHGVVYITE NKNKTVVIPC LGSISNLNVS LCARYPEKRF VPDGNRISWD

       190         200         210         220         230         240
SKKGFTIPSY MISYAGMVFC EAKINDESYQ SIMYIVVVVG YRIYDVVLSP SHGIELSVGE

       250         260         270         280         290         300
KLVLNCTART ELNVGIDFNW EYPSSKHQHK KLVNRDLKTQ SGSEMKKFLS TLTIDGVTRS

       310         320         330         340         350         360
DQGLYTCAAS SGLMTKKNST FVRVHEKPFV AFGSGMESLV EATVGERVRI PAKYLGYPPP

       370         380         390         400         410         420
EIKWYKNGIP LESNHTIKAG HVLTIMEVSE RDTGNYTVIL TNPISKEKQS HVVSLVVYVP

       430         440         450         460         470         480
PQIGEKSLIS PVDSYQYGTT QTLTCTVYAI PPPHHIHWYW QLEEECANEP SQAVSVTNPY

       490         500         510         520         530         540
PCEEWRSVED FQGGNKIEVN KNQFALIEGK NKTVSTLVIQ AANVSALYKC EAVNKVGRGE

       550         560         570         580         590         600
RVISFHVTRG PEITLQPDMQ PTEQESVSLW CTADRSTFEN LTWYKLGPQP LPIHVGELPT

       610         620         630         640         650         660
PVCKNLDTLW KLNATMFSNS TNDILIMELK NASLQDQGDY VCLAQDRKTK KRHCVVRQLT

       670         680         690         700         710         720
VLERVAPTIT GNLENQTTSI GESIEVSCTA SGNPPPQIMW FKDNETLVED SGIVLKDGNR.
```

Figure 1 (contd.)

```
      730        740        750        760        770        780
NLTIRRVRKE DEGLYTCQAC SVLGCAKVEA FFIIEGAQEK TNLEIIILVG TAVIAMFFWL

      790        800        810        820        830        840
LLVIILRTVK RANGGELKTG YLSIVMDPDE LPLDEHCERL PYDASKWEFP RDRLKLGKPL

      850        860        870        880        890        900
GRGAFGQVIE ADAFGIDKTA TCRTVAVKML KEGATHSEHR ALMSELKILI HIGHHLNVVN

      910        920        930        940        950        960
LLGACTKPGG PLMVIVEFCK FGNLSTYLRS KRNEFVPYKT KGARFRQGKD YVGAIPVDLK

      970        980        990       1000       1010       1020
RRLDSITSSQ SSASSGFVEE KSLSDVEEEE APEDLYKDFL TLEHLICYSF QVAKGMEFLA

     1030       1040       1050       1060       1070       1080
SRKCIHRDLA ARNILLSEKN VVKICDFGLA RDIYKDPDYV RKGDARLPLK WMAPETIFDR

     1090       1100       1110       1120       1130       1140
VYTIQSDVWS FGVLLWEIFS LGASPYPGVK IDEEFCRRLK EGTRMRAPDY TTPEMYQTML

     1150       1160       1170       1180       1190       1200
DCWHGEPSQR PTFSELVEHL GNLLQANAQQ DGKDYIVLPI SETLSMEEDS GLSLPTSPVS

     1210       1220       1230       1240       1250       1260
CMEEEEVCDP KFHYDNTAGI SQYLQNSKRK SRPVSVKTFE DIPLEEPEVK VIPDDNQTDS

     1270       1280       1290       1300       1310       1320
GMVLASEELK TLEDRTKLSP SFGGMVPSKS RESVASEGSN QTSGYQSGYH SDDTDTTVYS

     1330       1340       1350
SEEAELLKLI EIGVQTGSTA QILQPDSGTT LSSPPV
```



pVAX10.VR2-1
7580 bp
CMV
VEGFR-2
Kanamycin
Rop
f1 ori
BglI - 445 - C'CryG_G
StyI - 445 - C'CwwG_G
StyI - 1641 - C'CwwG_G
BglI - 1763 - C'CryG_G
StyI - 1800 - C'CwwG_G
StyI - 2646 - C'CwwG_G
BamHI - 3156 - G'GATC_C
BglI - 3261 - C'CryG_G
StyI - 3740 - C'CwwG_G
XhoI - 4816 - C'TCGA_G
StyI - 5193 - C'CwwG_G
StyI - 5816 - C'CwwG_G
BglI - 5816 - C'CryG_G

Figure 2:

Figure 3:



n=1 VXM01 n=1 Placebo
n=2 VXM01 n=1 Placebo
n=3 VXM01 n=1 Placebo
10^{10}
10^{9}
10^{8}
10^{7}
10^{6}
DSMB
Decision
3rd cohort per dose group
included according to DSMB decision based on DLT

Figure 4:



VXM01
4 Administrations
Day 1, 3, 5, 7
D -21 to -1
Screening Visit
Medical History
Inclusion Criteria
Exclusion Criteria
D 0
Baseline Visit
Medical History
Randomisation
Immuno Monitoring
D 10
End of Treatment Visit
Adverse Events
Immuno Monitoring
Shedding
D 38
End of Study Visit
Adverse Events
Immuno Monitoring
Screening Period
Treatment Period
Follow-Up
Gemcitabine Background Therapy Day 1, 8 and 15 of each Chemotherapy Cycle
D 1
D 8
D 15
D 22
D 29
D 1
D 8
D 15
D 29

Figure 5:




Figure 6:




Figure 7:




Figure 8:




Figure 9:




Figure 10:




Figure 11:




Branch I
Branch II
Plating method
VXM01 Liquid Enrichment Culture
Cultivation on Kanamycin Plates
Visual Discrimination of Morphotypes
Cultivation on Kanamycin Plates
Serological VXM01 Confirmation
Liquid Culture PCR of Each Morphotype
Liquid Culture
PCR on Presence of Plasmid
Cultivation on Kanamycin Plates
Serological VXM01 Confirmation
Horizontal Plasmid Transfer
Detection Live VXM01

Figure 12:


Patients transiently shedding VXM01
100%
80%
60%
40%
20%
0%
0/15
0/6
0/6
0/6
1/6
1/6
Placebo
VXM01 10E6
VXM01 10E7
VXM01 10E8
VXM01 10E9
VXM01 10E10